Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Udenafil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil
    Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil

    31 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-pharma-receives-clear-fda-path-forward-for-the-approval-of-udenafil-for-single-ventricle-heart-disease-301558085.html

    PRNEWSWIRE
    31 May 2022
    Share Share
    Mezzion Announces Re-Submission of NDA for its Orphan Drug Udenafil
    Mezzion Announces Re-Submission of NDA for its Orphan Drug Udenafil

    26 Mar 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-announces-re-submission-of-new-drug-application-for-its-orphan-drug-udenafil-to-treat-patients-who-have-undergone-the-fontan-operation-for-single-ventricle-heart-disease-301257235.html

    PRNEWSWIRE
    26 Mar 2021
    Share Share
    Mezzion Pharma announces that it has conducted a Type C Meeting with the FDA
    Mezzion Pharma announces that it has conducted a Type C Meeting with the FDA

    10 Oct 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-pharma-announces-that-it-has-conducted-a-type-c-meeting-with-the-fda-regarding-the-top-line-data-from-the-fuel-phase-3-clinical-trial-300936949.html

    PR NEWSWIRE
    10 Oct 2019
    Share Share
    Mezzion Hires Pol Pharma and Halo Pharma and Accuses Dr Reddy's of Fraud
    Mezzion Hires Pol Pharma and Halo Pharma and Accuses Dr Reddy's of Fraud

    02 Feb 2017

    // G MacDonald IN PHARMATECHNOLOGIST

    http://www.in-pharmatechnologist.com/Ingredients/Mezzion-hires-replacement-CMOs-and-says-Dr.-Reddy-s-hid-cGMP-problems

    G MacDonald IN PHARMATECHNOLOGIST
    02 Feb 2017
    Share Share
    Mezzion sues Dr. Reddy's for Fraud
    Mezzion sues Dr. Reddy's for Fraud

    25 Jan 2017

    // Eric Palmer FIERCE PHARMA

    http://www.fiercepharma.com/manufacturing/mezzion-sues-dr-reddy-s-for-fraud-citing-plant-problems-cost-it-a-drug-approval

    Eric Palmer FIERCE PHARMA
    25 Jan 2017
    Share Share
    Mezzion Receives SPA Agreement From FDA For Udenafil Phase 3 Studies
    Mezzion Receives SPA Agreement From FDA For Udenafil Phase 3 Studies

    23 Mar 2016

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/mezzion-pharma-receives-special-protocol-assessment-spa-agreement-from-fda-for-udenafil-phase-3-studies-in-adolescents-with-single-ventricle-congenital-heart-disease-with-fontan-physiology-300240463.html

    PR NEWSWIRE
    23 Mar 2016
    Share Share